OSR控股公司宣布委任Andreas Niethammer博士为旗下公司Vaximm的首席医疗官,他将负责推动临床策略和业务扩张。Niethammer博士在癌症免疫治疗领域拥有深厚背景,曾共同创立Vaximm。此番任命后,他将领导口服T细胞激活剂的研发工作,重点关注核心候选药物VXM01的开发进程。
OSR控股公司宣布委任Andreas Niethammer博士为旗下公司Vaximm的首席医疗官,他将负责推动临床策略和业务扩张。Niethammer博士在癌症免疫治疗领域拥有深厚背景,曾共同创立Vaximm。此番任命后,他将领导口服T细胞激活剂的研发工作,重点关注核心候选药物VXM01的开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.